Igen bioterror defense
This article was originally published in The Gray Sheet
Executive Summary
Origen biothreat environmental detection product contract with Department of Defense's Joint Program Executive Office for Chemical & Biological Defense will bring in $23 mil. over four years and double the firm's biodefense revenues over the next year, Igen says. During FDA's April Science Forum, PEO-CBD said its initial protocol likely would be a Roche Taqman PCR-type device (1"The Gray Sheet" May 5, 2003, p. 10)...
You may also be interested in...
Defense Department To Award Bioterror Testing Platform Contract By Summer
The diagnostic platform targeted by the Department of Defense's bioterrorism acquisition process likely will include electrochemiluminescence (ECL) technology, according to DoD
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.